A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting where good ideas are being implemented, it encourages their wider uptake.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Overall ranking Vacancies Funding Methodology Key Finding
Investor Engagement Manager

Bowen Gu

Email: bgu@accesstomedicinefoundation.org

Bowen Gu  is an Investor Engagement Researcher in the Strategy Team of the Access to Medicine Foundation. Bowen has five years’ experience in responsible investment. She joined the Access to Medicine Foundation upon completion of a German Chancellor Fellowship looking into the European responsible investment ecosystem in comparison with China. Prior to this, Bowen worked as a consultant with CSR Asia in Hong Kong and as an analyst with the ESG research provider Sustainalytics in Singapore.

Bowen holds a Master’s Degree from the Erasmus Mundus program in Environmental Sciences, Policy and Management (MESPOM) and a Bachelor’s Degree in Mathematical Sciences from Tsinghua University in China.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.